Copper Mining Market in Asia-Pacific to 2020

Stribild Introduction to Reinforce HIV/AIDS Revenues as Key Patents Expire
 
 
Spread the Word
Listed Under

Tags:
Global Markets Direct
Market Research
Metal And Mining
Copper Mining Market

Industry:
Marketing

Location:
London, Greater - England

Nov. 20, 2012 - PRLog -- Gilead Science’s combination drug Stribild (previously known as the “Quad pill”) is expected to bolster the HIV/AIDS therapeutics market as a number of significant medications go off-patent over the next few years, states business intelligence provider.

Forecasts from the firm’s latest report indicate that the global HIV/AIDS therapeutics market will increase in value at a Compound Annual Growth Rate (CAGR) of 7% between the years 2011 and 2018, from $13.5 billion to $21.8 billion.

As a consequence of the on-going patent-cliff, this predicted growth rate is less than the market experienced in previous years. Between 2004 and 2011, the market experienced a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva and Reyataz (both produced by Bristol-Myers Squibb) in 2014 and 2017 respectively, a more modest increase is predicted.

However, the market is not without promise. The multi-class fixed dose combination tablet from Gilead Sciences, Atripla, saw global revenue increase from $2.9 billion in 2010 to $3.2 billion last year, while potential blockbuster Stribild was approved by the US Food and Drug Administration in August of this year and is expected to make a major impact.

Gilead announced Stribild's initial price as $28,500, which is one-third greater than that of Atripla, but with impressive efficacy and strong patient compliance, We do not expect this higher cost to be a significant barrier to widespread use.

Last year’s sales figures show Gilead as being the greatest revenue shareholder of the world’s top seven markets, with 36%. With less than half of that number, Bristol-Myers Squibb came second with 16%, while ViiV Healthcare completed the top three with a 13% segment.

This report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018.

For Sample Pages, please click or add the below link to your browser:

http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?...

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our  team of industry experts.

We are market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.


Visit our Report Store

http://www.globalmarketsdirect.com

For more details contact:

pressreleases@globalmarketsdirect.com (mailto:pressreleases@globalmarketsdirect.com%20)
End
Source:
Email:***@globalmarketsdirect.com Email Verified
Phone:+914066166782
Zip:EC4Y 0AN
Tags:Global Markets Direct, Market Research, Metal And Mining, Copper Mining Market
Industry:Marketing
Location:London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Global Markets Direct PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share